Bioventus Inc.

NASDAQ:BVS

Medical - Devices

Healthcare
$10.62 +2.11%

+$0.18 today

Market cap
$727.20M
Beta
0.67
P/E (TTM)
20.6
EPS (TTM)
$0.42
52W Low $5.81High $11.25

Volume 0.70M

Average 0.56M

BVS Deferred Tax Liabilities

Taxes owed in future periods because of timing differences between accounting and tax rules.

Bioventus Inc.NASDAQ: BVS

Deferred Tax Liabilities · Q1 FY2026 · quarter ended Mar 2026

Deferred tax liabilities falls 6.4% from a year ago

Deferred tax liabilities stood at $568K at the end of Q1 FY2026, down 6.4% from a year earlier and up 31.2% from the prior quarter. Over 3 fiscal years it compounded at -42.2% a year.

Context

  • Deferred tax liabilities amounted to 0.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Deferred tax liabilities increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether deferred tax liabilities keeps falling in the next quarterly balance sheet after a -6.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$568K+31.2% QoQ
Last fiscal yearDec 2025
$433K-23.2% YoY
Year agoMar 2025
$607K-6.4% since
Deferred Tax Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.4%——
1 year-23.2%——
3-year CAGR-42.2%——
5-year CAGR——
10-year CAGR——

Deferred Tax Liabilities history

USD · from the balance sheet

Latest · FY2025
433K USD
Year-over-year change
-23.2%
4-year CAGR
-76.1%

Deferred Tax Liabilities vs competitors

How BVS compares with its peers on the latest reported figures

  • BVS's Mar 2026 deferred tax liabilities of $568K is the 3rd highest of the 9 companies compared; the peer median is $0.
  • Its year-over-year change of -6.4% is the 2nd highest of 4, against a peer median of -89.3%.
  • Deferred tax liabilities amounts to 0.1% of total assets for BVS, versus a peer median of 0.0%.
BVS Competitors Peer median
Deferred Tax Liabilities for BVS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SNNSmith & Nephew plcDec 2025$40M +29.0%+3.6%0.4%
IARTIntegra LifeSciences Holdings CorporationMar 2026$6.14M -89.3%-55.3%0.2%
BVSBioventus Inc.Mar 2026$568K -6.4%-42.2%0.1%
MDXGMiMedx Group, Inc.Mar 2026$0 ——0.0%
OFIXOrthofix Medical Inc.Mar 2026$0 ——0.0%
ANIKAnika Therapeutics, Inc.Mar 2026$0 ——0.0%
ORGOOrganogenesis Holdings Inc.Mar 2026$0 ——0.0%
XTNTXtant Medical Holdings, Inc.Mar 2026$0 -100.0%—0.0%
TELATELA Bio, Inc.Jun 2026$0 ——0.0%
Peer median (excluding BVS) $0-89.3%-25.9%0.0%

Competitors are the stored peer set for BVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents43.93M30.19M36.96M41.58M51.24M
Short-term Investments00000
Net Receivables124.96M136.3M122.79M127.39M128.3M
Inventory61.69M84.77M91.33M92.48M82.24M
Other Current Assets20.28M16.89M16.91M14.16M11.07M
Total Current Assets263.1M272.58M268M275.61M272.84M
Property, Plant & Equipment (Net)40.17M44.15M49.96M33.52M27.02M
Goodwill147.62M7.46M7.46M7.46M7.46M
Intangible Assets695.19M639.85M482.35M404.73M368.42M
Long-term Investments29.29M2.64M000
Tax Assets481K004.75M5.52M
Other Non-current Assets50M405.98M3.14M1.89M2.29M
Total Non-current Assets962.76M1.1B542.91M452.35M410.72M
Total Assets1.23B1.37B810.91M727.96M683.56M
Account Payables16.92M36.7M23.04M23.69M10.93M
Short-term Debt18.04M33.06M27.85M27.34M19.21M
Tax Payables8.14M2.57M4.75M3.87M0
Deferred Revenue00000
Other Current Liabilities46.48M151.07M34.23M51.13M93.51M
Total Current Liabilities180.86M304.02M175.5M210.4M160.38M
Long-term Debt339.64M385.01M367M308.29M278.95M
Deferred Tax Liabilities133.52M2.25M1.21M564K433K
Deferred Revenue (Non-current)00000
Other Non-current Liabilities38.05M269.15M46.08M23.1M2.16M
Total Non-current Liabilities511.21M656.41M414.3M331.95M294.73M
Total Liabilities692.07M960.43M589.79M542.35M455.11M
Common Stock75K78K79K82K83K
Retained Earnings(6.6M)(165.31M)(321.54M)(355.08M)(334.93M)
Accumulated OCI179K(110K)794K(2.57M)(1.9M)
Other Stockholders Equity00000
Minority Interest74.87M86.98M47.53M37.66M44.34M
Total Equity533.79M412.22M221.12M185.6M228.45M
Total Debt357.68M418.07M394.85M335.63M311.35M
Net Debt313.75M387.88M357.88M294.05M260.11M

Bioventus Inc.

NASDAQ:BVS

Intrinsic Alpha fair value

Locked

Current Price

$10.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.